Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OROS hydromorphone vs sustained-release oxycodone for chronic non-malignant pain
2004-005187-24Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Chronic non-cancer pain (CNCP) comparing OROS hydromorphone once-daily with Sustained-release oxycodone twice-daily (2 arms). Started Aug 2005; status: completed.
02
Drugs
hydromorphoneoxycodone
03
Conditions
Chronic non-cancer pain (CNCP)
Beyond the preview
Go deeper on 2004-005187-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005187-24.